Article and Video CATEGORIES
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients
Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
Article
Da click aquí para más información y para registrarte ahora
Forum Discussions
Hi Ascardino, Welcome to Grace. I'm so sorry to hear of your situation. While we don't have specific info or expertise on ovarian cancer, I did some searching for information. It...
Hello Janine,
Thank you for sharing this valuable leukemia playlist—building a reliable knowledge base like this truly makes a difference for everyone navigating such a challenging journey. I appreciate the open...
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
I don't know what to do. No insurance